Direct health care costs for children with pervasive developmental disorders: 1996-2002

Area of Science:

• Pediatric Health Economics
• Developmental Psychology
• Public Health Policy

Background:

• Pervasive Developmental Disorder (PDD) presents unique challenges in pediatric healthcare.
• Understanding the economic impact of chronic pediatric conditions is crucial for resource allocation.
• Previous research has not fully elucidated the direct treatment costs of PDD relative to other common pediatric diseases.

Purpose of the Study:

• To compare the direct healthcare treatment costs of Pervasive Developmental Disorder (PDD) with those of asthma and diabetes in children.
• To quantify the economic burden of PDD in a pediatric population using real-world data.

Main Methods:

• A retrospective claims-based study utilizing the California Medicaid (Medi-Cal) database from 1996-2002.
• Identification and matching of 731 children diagnosed with PDD with control groups of children with asthma and diabetes based on sex.
• Analysis of mean total healthcare costs post-diagnosis for each condition.

Main Results:

• Mean total healthcare costs for children with PDD were significantly higher, ranging from two to threefold greater than for asthma and diabetes.
• Specific mean costs: PDD ($4,815), Asthma ($1,469), Diabetes ($2,404).
• Statistical significance was established (P < 0.0001).

Conclusions:

• Children diagnosed with Pervasive Developmental Disorder (PDD) incur substantially greater direct healthcare costs compared to children with asthma or diabetes.
• The findings underscore the significant economic burden of PDD on healthcare systems.
• This research provides critical data for healthcare policy and resource planning for pediatric chronic conditions.